Connect with us

Technology

Ginkgo Bioworks Reports Third Quarter 2024 Financial Results

Published

on

Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions

Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck 

BOSTON, Nov. 12, 2024 /PRNewswire/ — Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2024. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information will be available at investors.ginkgobioworks.com.

Third Quarter 2024 Financial Results

Third quarter 2024 Total revenue of $89 million, up from $55 million in the comparable prior year period, an increase of 61% driven by $45 million of non-cash revenue from a release of deferred revenue relating to the mutual termination of a customer agreement. Excluding this impact, Total revenue in the quarter was $44 million, a decrease of 21% over the prior year periodExcluding the $45 million non-cash deferred revenue release, third quarter 2024 Cell Engineering revenue of $30 million, down from $37 million in the comparable prior year period, a decrease of 20% driven by the continued shift from early stage customers to large/enterprise customers along with commercial changes related to the restructuringThird quarter 2024 Biosecurity revenue of $14 million with gross profit margin of 28%. Biosecurity revenue decreased from the comparable prior year period due to the expected ramp down of K-12 testingThird quarter 2024 Loss from operations of $(55) million (inclusive of stock-based compensation expense of $14 million and M&A and restructuring related costs of $2 million, net), compared to Loss from operations of $(286) million (inclusive of stock-based compensation expense of $54 million and M&A and restructuring related costs, including asset impairments, of $124 million) in the comparable prior year period. The 2024 period also benefited from the above non-cash deferred revenue releaseThird quarter 2024 Adjusted EBITDA of $(20) million, up from $(84) million in the comparable prior year period, driven by the above non-cash deferred revenue release and a decrease in operating expensesCash and cash equivalents balance as of the end of the third quarter of $616 million

“I’m extremely proud of the significant progress we made in the third quarter,” said Jason Kelly, co-founder and CEO of Ginkgo. “The team has been laser-focused on delivering for customers while driving down costs even further. We are achieving ambitious milestones, signing new deals with several new and existing customers while also launching our new Automation, Datapoints and AI offerings. Beyond customer successes, we will substantially consolidate our overall real estate footprint by exiting several facilities in Cambridge, MA and Europe by year end. We couldn’t have done this without the support of our Board and we’re very grateful to Arie for all of his service and contributions to our journey since going public, and look forward to working closely with Sri as he brings a wealth of knowledge in the automation and life science tools space as we expand increasingly into tools. It’s an incredibly important time to be pursuing the mission of making biology easier to engineer and creating sustainable biosecurity infrastructure for the future. I am excited by the momentum we are gaining to meet that mission as we close out this year on a substantially reduced cost base.”

Recent Business Highlights & Strategic Positioning

Cell Engineering closed deals with new and existing customersAdded 25 new programs and other customer contracts to the Cell Engineering platform in Q3 2024, of which 11 were comparable in size and scope to historically reported New Programs and an additional 14 contracts that represent a variety of other deal archetypes, such as Datapoints projectsSigned a new deal with Novo Nordisk focused on the discovery and development of proteins while also expanding Ginkgo’s existing collaboration on expression systems for pharmaceutical productsDelivered on a major research milestone for Ginkgo’s previously announced deal with Merck. As part of this milestone completion, Ginkgo will receive a fee of $9 million in cash, expected in Q4 2024, and will move to Stage 2 to work towards making an even more effective production processSigned three new Datapoints deals with a major TechBio company and two of the top 25 pharmaceutical companiesGinkgo Biosecurity continues to work towards creating solutions that offer persistent, pervasive monitoringGinkgo validated its approach to rapidly detect H5N1 and has updated its offerings to include DNA sequencing of raw milk, bioinformatics as a service and comprehensive analyzed data setsGinkgo made significant progress on its plan to reach Adjusted EBITDA breakeven by the end of 2026The reduction in force is estimated to achieve over $85 million in annualized savings by mid-2025Ginkgo has continued implementing significant non-people cost cutting measures, including rationalizing third-party costs and site consolidationDr. Sri Kosuri, CEO of Octant and former associate professor at UCLA in the Chemistry and Biochemistry Department, joined our Board on November 6, 2024. Dr. Arie Belldegrun, a director since September 2021 and member of our compensation committee, resigned from the Board on November 7, 2024

Full Year 2024 Outlook

Ginkgo previously issued 2024 guidance for Total revenue of $170-190 million; Cell Engineering services revenue of $120-140 million; and Biosecurity revenue of at least $50 million. Ginkgo updates its previously issued guidance solely to reflect the impact of the previously mentioned $45 million non-cash deferred revenue release in the third quarter to:Total revenue guidance of $215-235 million in 2024;Cell Engineering services revenue of $165-185 million in 2024; andBiosecurity revenue of at least $50 million in 2024.

Conference Call Details
Ginkgo will host a videoconference today, Tuesday, November 12, 2024, beginning at 5:30 p.m. ET. The presentation will include an overview of third quarter financial performance, recent business updates, a discussion on Ginkgo’s outlook, as well as a moderated question and answer session.

To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.

A webcast link is available on Ginkgo’s Investor Relations website and a replay will be made available following the presentation.

Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/

Audio-Only Dial Ins:
+1 646 876 9923 (New York)
+1 301 715 8592 (Washington DC)
+1 312 626 6799 (Chicago)
+1 669 900 6833 (San Jose)
+1 253 215 8782 (Tacoma)
+1 346 248 7799 (Houston)
+1 408 638 0968 (San Jose)

Webinar ID: 920 8859 2008

If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our website at https://investors.ginkgobioworks.com/events/ for updated dial-in information.

About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats.  For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn.

Forward-Looking Statements of Ginkgo Bioworks
This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, including the timing for attaining Adjusted EBITDA breakeven and profitability, our reduction in workforce and anticipated impacts thereof, the timing and structuring of our facilities consolidation and the potential financial impact thereof, potential customer success, including successful application of our offerings by our customers, expectations with regard to revenue, expenses, including our stock-based compensation expenses, our full year 2024 outlook, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “can,” “project,” “potential,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo’s business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development or commercialization success of our customers, and (xi) the potential negative impact on our business of our planned reduction in force or the failure to realize the anticipated savings associated therewith. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Ginkgo’s annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 29, 2024 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

Use of Non-GAAP Financial Measures
Certain of the financial measures included in this release, including Adjusted EBITDA, have not been prepared in accordance with generally accepted accounting principles (“GAAP”), and constitute “non-GAAP financial measures” as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo’s financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation below for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo’s most comparable GAAP financial measures.

Ginkgo Bioworks Contacts:

INVESTOR CONTACT:
investors@ginkgobioworks.com 

MEDIA CONTACT:
press@ginkgobioworks.com 

 

Ginkgo Bioworks Holdings, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except per share data, unaudited)

As of September 30, 2024

As of December 31, 2023

Assets

Current assets:

Cash and cash equivalents

$                                  616,214

$                                 944,073

Accounts receivable, net

23,411

17,157

Accounts receivable – related parties

531

742

Prepaid expenses and other current assets

22,324

39,777

Total current assets

662,480

1,001,749

Property, plant, and equipment, net

211,035

188,193

Operating lease right-of-use assets

405,911

206,801

Investments

62,103

78,565

Intangible assets, net

79,566

82,741

Goodwill

49,238

Other non-current assets

59,788

58,055

Total assets

$                             1,480,883

$                            1,665,342

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$                                    15,700

$                                     9,323

Deferred revenue

22,894

44,486

Accrued expenses and other current liabilities

75,833

110,051

Total current liabilities

114,427

163,860

Non-current liabilities:

Deferred revenue, net of current portion

105,247

158,062

Operating lease liabilities, non-current

445,592

221,835

Other non-current liabilities

17,674

24,433

Total liabilities

682,940

568,190

Commitments and contingencies

Stockholders’ equity:

Preferred stock, $0.0001 par value

Common stock, $0.0001 par value

5

5

Additional paid-in capital

6,527,698

6,386,191

Accumulated deficit

(5,730,023)

(5,290,528)

Accumulated other comprehensive income

263

1,484

Total stockholders’ equity

797,943

1,097,152

Total liabilities and stockholders’ equity

$                             1,480,883

$                            1,665,342

 

Ginkgo Bioworks Holdings, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except per share data, unaudited)

Three Months Ended September 30,

Nine Months Ended September 30,

2024

2023

2024

2023

Cell Engineering revenue

$           75,089

$          37,176

$        139,183

$          116,555

Biosecurity revenue:

   Product

6,495

28,949

   Service

13,957

11,759

44,013

71,196

Total revenue

89,046

55,430

183,196

216,700

Costs and operating expenses:

   Cost of Biosecurity product revenue

906

7,481

   Cost of Biosecurity service revenue

9,987

6,017

30,996

39,913

   Cost of other revenue

2,016

3,930

   Research and development (1)

77,006

156,662

347,684

463,583

   General and administrative (1)

52,292

82,028

188,864

295,802

   Impairment of lease assets

96,210

96,210

   Goodwill impairment

47,858

   Restructuring charges

2,949

20,015

Total operating expenses

144,250

341,823

639,347

902,989

Loss from operations

(55,204)

(286,393)

(456,151)

(686,289)

Other income (expense):

   Interest income, net

9,251

15,020

31,275

43,914

   Loss on equity method investments

(1,516)

   Loss on investments

(6,912)

(36,324)

(16,282)

(44,815)

   Loss on deconsolidation of subsidiary

(7,013)

(7,013)

   Change in fair value of warrant liabilities

1,528

1,891

5,701

(1,387)

   Other income, net

1,572

2,893

2,821

9,045

Total other income (expense)

(1,574)

(16,520)

16,502

5,241

Loss before income taxes

(56,778)

(302,913)

(439,649)

(681,048)

Income tax expense (benefit)

(375)

(22)

(154)

127

Net loss

$      (56,403)

$     (302,891)

$     (439,495)

$       (681,175)

Net loss per share, basic and diluted

$          (1.08)

$           (6.21)

$           (8.58)

$           (14.09)

Weighted average common shares outstanding:

   Basic

52,240

48,770

51,244

48,330

   Diluted

52,246

48,770

51,250

48,330

Comprehensive loss:

Net loss

$     (56,403)

$     (302,891)

$     (439,495)

$  (681,175)

Other comprehensive income (loss):

   Foreign currency translation adjustment

494

(1,599)

(2,713)

(267)

   Reclassification of foreign currency translation

   adjustment realized upon sale of

   foreign subsidiary

1,492

1,492

Total other comprehensive income (loss)

1,986

(1,599)

(1,221)

(267)

Comprehensive loss

$     (54,417)

$     (304,490)

$     (440,716)

$       (681,442)

 (1) Total stock-based compensation expense, inclusive of employer payroll taxes, was allocated as follows (in thousands):

Three Months Ended September 30,

Nine Months Ended September 30,

2024

2023

2024

2023

Research and development

$             3,214

$         33,976

$         48,028

$         122,086

General and administrative

10,799

19,671

46,608

69,238

Total

$           14,013

$         53,647

$         94,636

$         191,324

 

Ginkgo Bioworks Holdings, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands, unaudited)

Nine Months Ended September 30,

2024

2023

Cash flows from operating activities:

Net loss

$                         (439,495)

$                          (681,175)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

47,368

57,670

Stock-based compensation

91,783

187,047

Goodwill impairment

47,858

Restructuring related impairment charges

4,823

Loss on investments and equity method investments

16,282

46,331

Loss on deconsolidation of subsidiary

7,013

Change in fair value of warrant liabilities

(5,701)

1,387

Change in fair value of contingent consideration liability

3,698

10,217

Non-cash lease expense

20,619

24,635

Non-cash in-process research and development

19,796

3,981

Impairment of long-lived assets

121,404

Other non-cash activity

655

3,053

Changes in operating assets and liabilities:

Accounts receivable

(6,101)

21,168

Prepaid expenses and other current assets

3,487

13,557

Operating lease right-of-use assets

19,224

9,277

Other non-current assets

(196)

(2,733)

       Accounts payable, accrued expenses and other current    liabilities

(31,099)

(4,822)

Deferred revenue, current and non-current

(67,779)

(29,382)

Operating lease liabilities, current and non-current

(11,383)

(18,310)

Other non-current liabilities

1,998

(974)

Net cash used in operating activities

(277,150)

(237,669)

Cash flows from investing activities:

Purchases of property and equipment

(48,831)

(37,355)

Business acquisition

(5,400)

Proceeds from sales of marketable securities

3,951

Proceeds from sale of equipment

591

3,000

Other

538

336

Net cash used in investing activities

(49,151)

(34,019)

Cash flows from financing activities:

Proceeds from exercise of stock options

84

79

Principal payments on finance leases

(694)

(977)

Contingent consideration payment

(922)

(1,082)

Other

(4)

(604)

Net cash used in financing activities

(1,536)

(2,584)

Effect of foreign exchange rates on cash and cash equivalents

(208)

(690)

Net decrease in cash, cash equivalents and restricted cash

(328,045)

(274,962)

Cash and cash equivalents, beginning of period

944,073

1,315,792

Restricted cash, beginning of period

45,511

53,789

Cash, cash equivalents and restricted cash, beginning of period

989,584

1,369,581

Cash and cash equivalents, end of period

616,214

1,049,244

Restricted cash, end of period

45,325

45,375

Cash, cash equivalents and restricted cash, end of period

$                           661,539

$                          1,094,619

 

Selected Non-GAAP Financial Measures

(in thousands, unaudited)

Three Months Ended September 30,

Nine Months Ended September 30,

2024

2023

2024

2023

Net loss (1)

$        (56,403)

$       (302,891)

$        (439,495)

$       (681,175)

Interest income, net

(9,251)

(15,020)

(31,275)

(43,914)

Income tax expense (benefit)

(375)

(22)

(154)

127

Depreciation and amortization

17,171

21,060

47,368

57,670

EBITDA

(48,858)

(296,873)

(423,556)

(667,292)

Stock-based compensation (2)

14,013

53,647

94,636

191,324

Impairment expense (3)

112,403

47,858

121,404

Restructuring charges (4)

2,949

20,015

Merger and acquisition related expenses (5)

(796)

12,253

6,110

43,127

Loss on equity method investments

1,516

Loss on investments

6,912

36,324

16,282

44,815

Loss on deconsolidation of subsidiary

7,013

7,013

Change in fair value of warrant liabilities

(1,528)

(1,891)

(5,701)

1,387

Change in fair value of convertible notes

281

317

1,127

121

Adjusted EBITDA

$        (20,014)

$        (83,820)

$        (236,216)

$        (263,598)

(1)

All periods include non-cash revenue when earned, including $45.4 million in the three and nine months ended September 30, 2024, recognized pursuant to the termination of revenue contracts with Motif.

(2)

Includes $0.2 million and $1.1 million in employer payroll taxes for the three months ended September 30, 2024 and 2023, respectively, and $2.9 and $4.3 million for the nine months ended September 30, 2024 and 2023, respectively.

(3)

For 2024, includes $47.9 million related to goodwill impairment. For the three months ended September 30, 2023, includes a $16.2 million impairment loss on lab equipment and a $96.2 million impairment loss on an operating lease right-of-use asset and related leasehold improvements associated with an exited Zymergen leased facility. For the nine months ended September 30, 2023, includes a $25.2 million impairment loss on lab equipment and a $96.2 million impairment loss on lease assets associated with the exited Zymergen leased facility.

(4)

Restructuring charges consist of employee termination costs from the reduction in force commenced in June 2024, as well as the impairment of a right-of-use asset relating to facilities consolidation.

(5)

Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs, net of insurance recovery. Not included in this adjustment are non-cash charges for acquired in-process research and development expenses, which totaled $19.8 million and $4.0 million in the nine months ended September 30, 2024 and 2023, respectively.

 

Ginkgo Bioworks Holdings, Inc.

Segment Information

(in thousands, unaudited)

Three Months Ended September 30,

Nine Months Ended September 30,

2024

2023

2024

2023

Revenue:

Cell Engineering

$          75,089

$         37,176

$       139,183

$       116,555

Biosecurity

13,957

18,254

44,013

100,145

Total revenue

89,046

55,430

183,196

216,700

Segment cost of revenue:

Cell Engineering

2,016

3,930

Biosecurity

9,987

6,923

30,996

47,394

Segment research and development expense:

Cell Engineering

57,201

90,889

253,790

275,494

Biosecurity

141

313

720

1,408

Total segment research and development expense

57,342

91,202

254,510

276,902

Segment general and administrative expense:

Cell Engineering

29,319

42,617

103,167

155,216

Biosecurity

10,040

12,207

33,169

42,862

Total segment general and administrative expense

39,359

54,824

136,336

198,078

Segment operating (loss) income:

Cell Engineering

(13,447)

(96,330)

(221,704)

(314,155)

Biosecurity

(6,211)

(1,189)

(20,872)

8,481

Total segment operating loss

(19,658)

(97,519)

(242,576)

(305,674)

Operating expenses not allocated to segments:

Stock-based compensation (1)

14,013

53,647

94,636

191,324

Depreciation and amortization

17,171

21,060

47,368

57,670

Impairment expense (2)

112,403

47,858

121,404

Restructuring charges

2,949

20,015

Change in fair value of contingent consideration liability

1,413

1,764

3,698

10,217

Loss from operations

$      (55,204)

$    (286,393)

$    (456,151)

$    (686,289)

(1)

Includes $0.2 million and $1.1 million in employer payroll taxes for the three months ended September 30, 2024 and 2023, respectively, and $2.9 million and $4.3 million in employer payroll taxes for the nine months ended September 30, 2024 and 2023, respectively.

(2)

For 2024, includes $47.9 million related to goodwill impairment. For the three months ended September 30, 2023, includes a $16.2 million impairment loss on lab equipment and a $96.2 million impairment loss on an operating lease right-of-use asset and related leasehold improvements associated with an exited Zymergen leased facility. For the nine months ended September 30, 2023, includes a $25.2 million impairment loss on lab equipment and a $96.2 million impairment loss on lease assets associated with the exited Zymergen leased facility.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-reports-third-quarter-2024-financial-results-302303182.html

SOURCE Ginkgo Bioworks

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

The total mileage of UAV transmission line inspection of State Grid Turfan Power Supply Company exceeded 50,000 kilometers

Published

on

By

TURFAN, China, Nov. 26, 2024 /PRNewswire/ — On November 22, the transmission and operation inspection center of State Grid Turfan Power Supply Company successfully completed the line inspection task of the 110 thousand volt Jiaolang line, marking the company’s 389th unmanned aerial vehicle inspection task in the year. Since 2016, the State Grid Turfan Power Supply Company has actively applied and promoted UAV inspection technology, and has achieved full coverage of UAV transmission line inspection in complex terrain such as mountains, deserts, and Gobi.

The complex and diverse terrain of Turfan, including high mountains, deserts and Gobi, has brought arduous challenges to the inspection of transmission lines. However, through the application of drone technology, the State Grid Turfan Power Supply Company has not only overcome these difficulties, but also achieved remarkable results in the operation and inspection of transmission lines. At the same time, with the intelligent upgrading and digital transformation of power grid equipment and management, UAV technology is widely used in maintenance and hanging, live monitoring, power grid construction and other fields, and the intelligent level of transmission line operation and inspection has been continuously improved. Up to now, the company’s drone inspection has covered 215 transmission lines of 35 thousand volts and above, with a total mileage of more than 50,000 kilometers, which is equivalent to the length of a week around the Earth’s equator.

In the next step, the State Grid Turfan Power Supply Company will continue to expand the application scenarios of UAVs, actively introduce new technologies and equipment, and accelerate the transformation of intelligent operation and inspection mode. The company plans to continuously improve the level of equipment operation and inspection, consolidate the foundation of equipment safety, and ensure the safe and stable operation of the power grid by further optimizing the drone inspection process and improving the data analysis and processing capabilities.

 

View original content:https://www.prnewswire.com/apac/news-releases/the-total-mileage-of-uav-transmission-line-inspection-of-state-grid-turfan-power-supply-company-exceeded-50-000-kilometers-302316063.html

SOURCE State Grid Turfan Power Supply Company

Continue Reading

Technology

MiniTool’s Biggest Discount of the Year During Black Friday and Cyber Monday

Published

on

By

VANCOUVER, BC, Nov. 25, 2024 /PRNewswire/ — MiniTool, a committed software development firm, offers MiniTool Partition Wizard, MiniTool Power Data Recovery, MiniTool ShadowMaker, MiniTool MovieMaker, MiniTool Video Converter, and other products in the 2024 Black Friday and Cyber Monday promotions. From November 25 to December 6, 2024, customers can visit the MiniTool promotion page to purchase products and enjoy big discounts.

Promotions and Activities

Entrance 1: Discounts for MiniTool Partition Wizard, MiniTool Power Data Recovery, and MiniTool ShadowMaker (UP TO 65% OFF)Entrance 2: Discounts for MiniTool MovieMaker and MiniTool Video Converter (UP TO 70% OFF)

MiniTool’s promotion is divided into three forms: lucky draw, combination promotion, and single item promotion.

Lucky Draw: Try your luck to get a discount or coupon for your desired single product. Each user has 5 chances per day during Black Friday sales.Combination Promotion: Or you can directly pick up your favorite bundles with a bigger discount!Single Item Promotion: Enjoy exclusive discounts on individual products!

Best Seller: MiniTool Partition Wizard Pro Ultimate + MiniTool ShadowMaker Pro Ultimate
MiniTool Partition Wizard is a top disk manager with comprehensive partition management features that can meet the basic disk and partition management needs of home and business users. It is available in Pro, Pro Platinum, and Pro Ultimate versions. Of these, the Pro Ultimate version is the best choice.

MiniTool ShadowMaker is a professional backup software based on the Windows system. It can safely back up files, folders, systems, disks, and partitions to internal or external hard drives.

MiniTool Partition Wizard Pro Ultimate and MiniTool ShadowMaker Pro Ultimate are originally priced at $199 and $158, respectively. During MiniTool’s Black Friday promotion, customers can buy these two products for ONLY $160.65 (55% OFF).

Double Protection of Data: MiniTool Power Data Recovery Personal Ultimate + MiniTool ShadowMaker Pro Ultimate
MiniTool Power Data Recovery is the best data recovery software for Windows users. It can successfully recover accidentally deleted files as well as files lost due to system crashes or virus attacks. Windows users can use MiniTool Power Data Recovery to recover data from internal storage, as well as external drives (such as HDD, SSD, USB, SD card, etc.).

MiniTool ShadowMaker can set up backup items regularly to properly protect your data and computer. It is the best choice for Windows users to back up files, hard drives, systems, etc.

MiniTool Power Data Recovery Personal Ultimate and MiniTool ShadowMaker Pro Ultimate charge $129 and $158 respectively. Now with a discount of 60% OFF, you ONLY NEED to PAY $114.80 for them.

65% OFF: MiniTool Partition Wizard Pro Platinum + MiniTool Power Data Recovery Personal Annual Subscription + MiniTool ShadowMaker Pro Annual Subscription
MiniTool Partition Wizard Pro Platinum offers all the features of the software, plus one year of free upgrades. It can be used on three devices after purchase. MiniTool Power Data Recovery Personal Annual Subscription offers all the functions of MiniTool data recovery software and a one-year free upgrade. MiniTool ShadowMaker Pro Annual Subscription allows use on two devices, plus one year of free updates.

The original prices of these three products are $129, $89, and $120 respectively. During the Black Friday promotion, you can get them all with ONLY $118.30 (65% OFF).

70% OFF: MiniTool MovieMaker Annual Subscription + MiniTool Video Converter 12-Month Subscription
MiniTool MovieMaker is the best choice for creating and editing videos. It supports adding transitions, special effects, and text to a video. Even beginners can make stunning videos with templates in MiniTool MovieMaker.

MiniTool Video Converter can convert audio and video into more than 1,000 formats. Its batch conversion function makes conversion more efficient. In addition, MiniTool Video Converter allows the recording of partial or full-screen activities without background noise.

The regular price of MiniTool MovieMaker Annual Subscription is $59.99, and the regular price of MiniTool Video Converter 12-Month Subscription is $119.99. During Black Friday, enjoy both of them for a whole year for ONLY $53.99, SAVING 70%!

For more product details, please visit the two promotion pages mentioned above.

About MiniTool® Software Ltd.
MiniTool® Software Ltd. is a software development company based in Canada. It is committed to providing customers with the most useful applications, such as MiniTool Power Data Recovery, MiniTool Partition Wizard, MiniTool ShadowMaker, MiniTool System Booster, MiniTool MovieMaker, and MiniTool Video Converter.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/minitools-biggest-discount-of-the-year-during-black-friday-and-cyber-monday-302316069.html

SOURCE MiniTool Software Limited

Continue Reading

Technology

Al Marwan Real Estate to Boost Residential Experience with Yardi

Published

on

By

Sharjah-based property management and development company to reshape residential communities and unify real estate processes with intuitive cloud technology

DUBAI, UAE, Nov. 25, 2024 /PRNewswire/ — Al Marwan Real Estate, the development and operations arm of Al Marwan Group, is set to centralise management operations and elevate residents’ experience with Yardi®. With one of the largest residential portfolios of corporate real estate and investment assets, Al Marwan is responsible for the development, procurement, leasing and operations of residential projects across the emirate of Sharjah.

The Yardi Residential Suite, including RentCafe, will allow Al Marwan to effectively manage and unify its property operations – from unit marketing and resident onboarding to accounting, billing and reporting. Yardi’s resident portal and app will further help residents to self-serve, manage details, log maintenance requests and view invoices. It will also aid in centralising communication with management teams, ensuring tenant requests and concerns are resolved efficiently.

“We are excited to embrace Yardi’s intuitive property management solution, elevate our operational efficiencies, and deliver unmatched services to our clients,” shared Majd Al Zaiem, Director of Al Marwan Real Estate. “With Yardi as our single real estate management platform, we can streamline tenant leases online and process them with record efficiency, enhance sustainability efforts by eliminating paper transactions and strengthen communication channels across our business.”

“The Yardi platform equips Al Marwan with a seamless solution, empowering the company to optimise its business strategy while effortlessly planning for future growth,” said Said Haider, senior director for Yardi. “We are excited to work with Al Marwan Real Estate in the UAE and look forward to helping them further digitise their operations across the region.”

See how Yardi can improve your resident’s experience with an end-to-end cloud solution.

About Al Marwan Group

Since its inception in 1978, Al Marwan Group has been offering unparalleled services to the construction, heavy equipment, investment, hospitality and real estate sectors. As a key player in the construction, machinery and real estate industries with an expertise spanning 5 decades. For more information, visit almarwangroup.com.

About Yardi

Yardi® develops and supports industry-leading investment and property management software for all types and sizes of real estate companies. With over 9,500 employees, Yardi is working with clients globally to drive significant innovation in the real estate industry. For more information on how Yardi is Energised for Tomorrow, visit yardi.ae.

Photo – https://mma.prnewswire.com/media/2566901/Yardi.jpg
Logo – https://mma.prnewswire.com/media/2447766/5046796/Yardi_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/al-marwan-real-estate-to-boost-residential-experience-with-yardi-302315618.html

Continue Reading

Trending